Open an account

Krystal Biotech

KRYS · NASDAQ

$325.42+$5.17 (+1.61%)TodayMarket closed ·
Prev close $320.25

About KRYS

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

Employees
295
Headquarters
Pittsburgh, Pennsylvania
Listed
Sep 20, 2017
Sector
Health Care
Industry
Biotechnology
Website
krystalbio.com

KRYS key statistics

Market cap
9.48B
Price-earnings ratio
40.13
Dividend yield
—
Average volume
261.45K
Volume
134.51K
Open price
$321.80
High today
$328.76
Low today
$321.26
52 Week high
$382.54
52 Week low
$183.03

Krystal Biotech (KRYS) at a glance

Krystal Biotech (KRYS) last traded at $325.42, with a market cap of 9.48B and a price-to-earnings ratio of 40.13.

Today the stock has traded between $321.26 and $328.76. The current price is 1.3% above the day's low and 1.0% below its high.

Volume so far is 134.51K shares, below the average of 261.45K shares a day.

Over the past year Krystal Biotech has ranged from $183.03 to $382.54, and now sits 71% of the way up that range.

Krystal Biotech met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $1.79 per share against an estimate of $1.69.

The average analyst price target is $378.79, 16.4% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 12 analyst ratings say Buy
  • Buy91.7%
  • Hold8.3%
  • Sell0.0%
Price target · 14 analystsAvg $378.79
Low
$217.15
Now
$325.42
High
$497.70

KRYS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 38.5% on average.

  1. Q3 FY24: reported $0.91 per share against an estimate of $0.9167
  2. Q4 FY24: reported $1.52 per share against an estimate of $1.19
  3. Q1 FY25: reported $1.20 per share against an estimate of $1.39
  4. Q2 FY25: reported $1.29 per share against an estimate of $1.15
  5. Q3 FY25: reported $2.66 per share against an estimate of $1.11
  6. Q4 FY25: reported $1.70 per share against an estimate of $1.44
  7. Q1 FY26: reported $1.83 per share against an estimate of $1.45
  8. Q2 FY26: reported $1.79 per share against an estimate of $1.69

KRYS news

  • Vandana Singh

    Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

  • Press releaseGlobe Newswire

    Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

  • Press releaseGlobe Newswire

    Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

  • Press releasePRNewswire

    Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

  • MHRA Approves Beremagene Geperpavec For The Treatment Of Dystrophic Epidermolysis Bullosa

  • Press releaseGlobe Newswire

    Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

  • Press releaseGlobe Newswire

    Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

  • Press releaseGlobe Newswire

    Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Similar companies

Companies in the same industry as Krystal Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.